NCT01397825View on ClinicalTrials.gov

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 9, 2011

Primary Completion Date

February 5, 2015

Study Completion Date

October 5, 2016

Conditions
Diffuse Large B-Cell LymphomaTransformed Follicular LymphomaMantle Cell LymphomaBurkitt's Lymphoma
Interventions
DRUG

Alisertib (MLN8237)

Alisertib (MLN8237) enteric coated tablet (ECT).

DRUG

Rituximab

Rituximab IV infusion.

DRUG

Vincristine

Vincristine IV Infusion.

Trial Locations (25)

Unknown

Tucson

Beverly Hills

Burbank

Miami

Lexington

Worcester

New York

Rochester

Chapel Hill

Philadelphia

Germantown

Memphis

Houston

San Antonio

Burlington

Orbassano

Genova

Palermo

Roma

Madrid

Seville

Aberdeen

London

Southampton

Birmingham

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT01397825 - MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine | Biotech Hunter | Biotech Hunter